Revvity (RVTY) investor relations material

Executive summary

• Q3 2025 revenue reached $699 million, up 2% year-over-year with 1% organic growth, driven by strong software and reproductive health segments.

• Adjusted EPS was $1.18, exceeding guidance midpoint but down 8% year-over-year; GAAP EPS was $0.40.

• Margins, cash flow, and capital deployment were managed effectively, with adjusted operating margin at 26.1%.

• Continued innovation, including AI-driven products and a new Type 1 Diabetes screening program, is driving future growth opportunities.

• New $1 billion share repurchase program authorized, replacing the prior program.

Financial highlights

• Q3 revenue was $699 million, up from $684 million year-over-year, with 1% organic growth.

• Adjusted operating margin was 26.1%, down from 28.3% year-over-year but above expectations.

• Adjusted EPS reached $1.18, $0.05 above guidance midpoint.

• Free cash flow was $120 million in Q3, with year-to-date free cash flow at $354 million, representing 89% conversion.

• Operating cash flow for the quarter was $138.6 million; cash and cash equivalents at quarter end were $931 million.

Outlook and guidance

• Full-year 2025 revenue guidance is $2.83–$2.88 billion, with 2%–4% organic growth reaffirmed.

• Adjusted EPS guidance raised to $4.90–$5.00 for full year 2025.

• 2026 outlook assumes 2%–3% organic growth and 28% adjusted operating margin baseline.

• Adjusted tax rate projected at 17% for 2025, with net interest and other expenses around $83 million.

• High single-digit EPS growth expected for 2026, with tax rate baseline at 18%.